R Retreatment in 1st Relapsed DLBCL

• Sponsor: Shanghai Jiao Tong University School of Medicine (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT00980304
• Collaborator: (none)
• Arm: 1

Study Details

Study Description

Brief Summary

It is a phase II , multicenter, open label clinical trial. Only the relapsed DLBCL patients after 1st line induction treatment of 6~8 cycles of RCHOP-like chemo will be enrolled to receive 3 cycles of RICE as salvage therapy.

After treatment each patient should be followed up for 2 years.

Condition or Disease	Intervention/Treatment	Phase
Lymphomas	Drug: Rituximab	Phase 2

Study Design

• Study Type: Interventional
• Official Title: A Multicenter, Open Label, Phase II Trial of Rituximab in Combination With ICE as Salvage Therapy in the Relapsed DLBCL Patients After 1st Line Induction Treatment of 6-8 Cycles of RCHOP-LIKE Chemo

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Rituximab in combination with ICE as salvage therapy	Drug: Rituximab

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Relapsed DLBCL patients having received 6 - 8 cycles of RCHOP-like chemotherapy as 1st line induction treatment.

2. Disease relapsed no earlier than 6 months after prior induction treatment.

3. Confirmed CD20 positivity of the lymphoma at time of diagnosis (prior to induction therapy)

4. ECOG performance status of 0, 1 or 2 at time of inclusion (see Appendix IV )

5. Known IPI at time of diagnosis (prior to induction therapy)

6. Age ≥18 years and <65 y

7. Life expectancy of > 3 months

8. Be willing and able to comply with the protocol for the duration of the study

9. Agree to use effective contraception for the entire treatment period and during the 12 months thereafter

10. Patient's written informed consent

Exclusion Criteria:

1. More than one prior chemoimmunotherapy regimen.

2. Histologies other than DLBCL according to the WHO/REAL classification

3. History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin, surgically treated malignant melanoma or carcinoma in situ of the cervix within the last 5 years.

4. Major surgery, other than diagnostic surgery, within the last 4 weeks.

5. Evidence of CNS involvement patients

6. Unacceptable hematologic status at baseline prior to study start below any of the values listed: WBC: <3 x 109/L; absolute neutrophil count (segmented + bands) <1.5 x 109/L; platelets: <100 x109/L

7. Abnormal liver function tests prior to study start above any of the values listed: serum bilirubin >2 mg/dL (30 mmol/L); ALAT or ASAT >2.5 x upper limit of normal range; or Abnormal renal function (serum creatinine > 150 μmol/L ).

8. HIV-positive patients.

9. Contraindication to the investigational medication

10. Active viral hepatitis, specifically HBV or HCV infection

11. Serious underlying medical conditions, (e.g. ongoing infection, uncontrolled diabetes mellitus, severe cardiac dysfunction or angina, gastric ulcers, active autoimmune disease)

12. Life expectancy < 3 months

13. Treatment within a clinical trial within 30 days prior to trial entry

14. Women who are breast feeding, are not using effective contraception, are pregnant

15. Patients under tutelage

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Shanghai Jiao Tong University School of Medicine

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00980304
• Other Study ID Numbers: ML22515
• First Posted: Sep 21, 2009
• Last Update Posted: Sep 21, 2009
• Last Verified: Sep 1, 2009

• Keywords provided by , ,: Diffuse large B cell lymphomas
• Additional relevant MeSH terms: Lymphoma; Rituximab

Study Results

No Results Posted as of Sep 21, 2009